Navigation Links
Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug Manufacturer to Provide Generic Version of donepezil HCl 23 mg
Date:8/29/2013

WOODCLIFF LAKE, N.J., Aug. 29, 2013 /PRNewswire/ -- Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of generic pharmaceuticals that grants certain rights, including the right to market and offer for sale a generic version of donepezil hydrochloride 23 mg and a non-exclusive license to Eisai Intellectual Property covering donepezil hydrochloride 23 mg, including U.S. Patent No. 8,481,565. This agreement applies to the United States only.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai'
'/>"/>

SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Eisai Launches New Website Providing Employers with Educational Resource for Obesity Management
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
4. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
5. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
6. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
7. FDA Grants Orphan Drug Status To Eisais Lenvatinib
8. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
9. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
10. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... TWi Pharmaceuticals, Inc. ("TWi") today announced ... with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals ... Inc. (individually and collectively, "Takeda") to settle and ... generic dexlansoprazole delayed release capsules for oral administration ... Abbreviated New Drug Application for TWi,s generic product ...
(Date:4/25/2015)... -- Hospira, Inc. (NYSE: HSP ... sprach heute auf der jährlichen Konferenz der Europäischen ... London über die Bedeutung von ... für Patienten. Das Unternehmen kündigte auch ... Titel „Why extrapolation is paramount to achieving ...
(Date:4/24/2015)... 24, 2015 Today, humanity takes a massive step ... and fat-free cronuts: 1-800 CONTACTS announces their new Apple Watch ... two taps. Two taps. New contacts. From your ... The app also features LensGauge which helps keep track of ... need to reorder. "Since our inception, we,ve been ...
Breaking Medicine Technology:TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2
(Date:4/27/2015)... Mirada, CA (PRWEB) April 27, 2015 ... minimally invasive treatments for nail fungi and infections. Onychomycosis, ... to affect up to 10% of adults in the ... fragility, and irregularity in thickness. , Healthpointe’s ... Institute , a branch dedicated to providing quality skincare ...
(Date:4/27/2015)... Miami, FL (PRWEB) April 27, 2015 ... policies from arresting nonviolent drug offenders to providing drug ... by Nepr on April 8th. Several states, ... cut state costs revolving incarceration. Texas has formed community ... populace. According to The Council of State Governments ...
(Date:4/27/2015)... April 27, 2015 Consumer Choice ... Service Providers in their respective sectors for Ottawa. We ... year’s winners; your dedication to superior service has resonated ... Canada, Consumer Choice Award gathers opinions, perceptions and expectations ... All winners have gone through a rigorous selection process ...
(Date:4/27/2015)... 2015 The Sanford J. Grossman Charitable ... Grossman, PhD, has committed $3 million to establish the ... Inflammatory Bowel Disease at the Icahn School of Medicine ... personalized medicine for treatment of Crohn’s disease, with the ... Crohn’s Disease, a chronic inflammatory disorder of the bowel ...
(Date:4/27/2015)... April 27, 2015 Final Cut Pro ... footage with ProTelestrator from Pixel Film Studios. A telestrator is ... sketch over a moving or still video image. Telestrators are ... analyze sports plays or incoming weather patterns. , After users ... then adjust the frame slider to control the speed of ...
Breaking Medicine News(10 mins):Health News:Southern California Healthpointe Clinics Now Treating Nail Fungus 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 3Health News:2015 Ottawa Consumer Choice Award-Winners 2Health News:2015 Ottawa Consumer Choice Award-Winners 3Health News:2015 Ottawa Consumer Choice Award-Winners 4Health News:2015 Ottawa Consumer Choice Award-Winners 5Health News:2015 Ottawa Consumer Choice Award-Winners 6Health News:2015 Ottawa Consumer Choice Award-Winners 7Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 2Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 3Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2
... has been discovered by researchers at Seoul National University. It ... highly expressed in lung cancer cells and also that patients ... study is published on March 31 in the open-access journal ... of the world,s most common cancers and a leading cause ...
... cancer organizations shows rates of death in the United States from ... and 2007. The findings come from the latest Annual Report to ... also finds that the overall rate of new cancer diagnoses for ... 1 percent per year for the same period. Edward J. ...
... from the University of Pittsburgh and Stanford University discovered ... role in the ability of one the world,s most ... possible role of similarly errant proteins in other diseases. ... the National Academy of Sciences ( PNAS ) ...
... the obesity epidemic, the National Institutes of Health is ... for NIH Obesity Research. More than one-third ... percent of the nation,s children are now obese, which ... including type 2 diabetes, heart disease, high blood pressure, ...
... a total of $383,000 for chronic obstructive pulmonary disease ... Institute (NHLBI), part of the National Institutes of Health, ... COPD Learn More Breathe Better campaign and will be ... The contract supports community-based public health efforts to ...
... continues to grow. Following the successful First International ... Second International Conference on Immune Tolerance will bring ... and insights into the mechanisms and treatment of ... inflammation and cancer. This Conference is supported by ...
Cached Medicine News:Health News:Pitt-Stanford research suggests aimless proteins crucial to disease 2Health News:New strategic plan for NIH obesity research seeks to curb epidemic 2Health News:NHLBI funds 9 organizations to improve awareness of COPD 2Health News:2nd International Conference on Immune Tolerance 2
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
... The VISULAS 690s is ... As the instrument of choice ... Visudyne clinical trials, Carl Zeiss ... legacy in laser manufacturing to ...
The SL 115 Classic Slit Lamp offers you high optical performance and convenient operation. It is not only the ideal instrument for all routine examinations and contact lens fitting, but is also excel...
Lens Loading and Folding for Multipiece & Single-Piece ACRYSOF Lens with Standard Forceps...
Medicine Products: